<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01424618</url>
  </required_header>
  <id_info>
    <org_study_id>39604</org_study_id>
    <nct_id>NCT01424618</nct_id>
  </id_info>
  <brief_title>A Novel Approach to Endometrial Preparation in Recipients of Donor Eggs</brief_title>
  <official_title>A Novel Approach to Endometrial Preparation in Recipients of Donor Cycles</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kelly, Maureen, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kelly, Maureen, M.D.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares two different methods to prepare the uterine lining of recipients for
      implantation in cycles using donor eggs. The study method requires less time than the
      standard method.

      It is hypothesized that both methods would be suitable for use in egg donor cycles.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Currently a combination of medications is used to prepare the uterine lining of recipients
      for implantation in egg donor cycles. The protocol used most commonly is as follows:
      Initially the individual's own pituitary-ovarian system is suppressed using a GnRH agonist so
      there are not conflicting signals sent to the uterus. This is followed by hormonal medication
      identical to what is secreted by the ovaries to prepare the uterine lining for subsequent
      embryo transfer in donor egg cycles.This preparation typically takes a minimum of four weeks.

      This study will compare a different medication, a GnRh antagonist (which is commonly used in
      IVF) to suppress an individual's system during the preparation of the uterine lining. This
      protocol would generally take only two weeks to prepare the uterine lining.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2006</start_date>
  <primary_completion_date type="Anticipated">September 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>endometrial thickness measured by ultrasound</measure>
    <time_frame>2-4 weeks</time_frame>
    <description>In office ultrasound to measure thickness of endometrial lining.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>endometrial biopsy</measure>
    <time_frame>3-6 weeks</time_frame>
    <description>In office aspiration of endometrial cells will be examined microscopically to determine if they are at an appropriate stage for implantation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Implantation, Embryo</condition>
  <arm_group>
    <arm_group_label>GnRh agonist</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm will use a GnRH agonist to suppress pituitary-ovarian function</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GnRH antagonist</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A GnRH antagonist will be used to suppress pituitary-ovarian function</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leuprolide</intervention_name>
    <description>leuprolide 10 units daily, decreased to 5 units daily once suppression achieved for a total of approximately 4 weeks. Once suppression achieved, estradiol and progesterone administered to mature uterine lining.</description>
    <arm_group_label>GnRh agonist</arm_group_label>
    <other_name>Lupron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ganirelix</intervention_name>
    <description>Ganirelix 250 mcg daily will be used to suppress pituitary-ovarian function and is administered concurrently with estradiol and progesterone for approximately two weeks.</description>
    <arm_group_label>GnRH antagonist</arm_group_label>
    <other_name>Antagon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  recipients awaiting egg donation

          -  some ovarian function

          -  normal endometrial cavity

        Exclusion Criteria:

          -  submucosal myoma

          -  myoma(s) greater than 4 centimeters

          -  endometrial polyp

          -  DES exposure

          -  documented recalcitrant thin endometrium ( &lt;7 mm)

          -  untreated vulvovaginitis

          -  active pelvic infection

          -  endometrial cancer or suspected/known hormonally sensitive cancers

          -  breast cancer

          -  thromboembolic disease

          -  cerebrovascular or coronary heart disease

          -  diabetes mellitus

          -  hepatic tumors or active liver disease

          -  severe hypertension

          -  headaches with neurologic disease

          -  cholestatic disease

          -  heavy smoking over age 35
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>52 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maureen Kelly, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Society Hill Reproductive Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dana Tillotson, BSN</last_name>
    <phone>215-829-8110</phone>
    <email>dtillotson@reproductivemedicinepa.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Society Hill Reproductive Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dana Tillotson, BSN</last_name>
      <phone>215-829-8110</phone>
      <email>dtillotson@reproductivemedicinepa.com</email>
    </contact>
    <investigator>
      <last_name>Maureen Kelly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2011</study_first_submitted>
  <study_first_submitted_qc>August 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2011</study_first_posted>
  <last_update_submitted>August 25, 2011</last_update_submitted>
  <last_update_submitted_qc>August 25, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 29, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kelly, Maureen, M.D.</investigator_affiliation>
    <investigator_full_name>Maureen Kelly, M.D.</investigator_full_name>
    <investigator_title>Medical Director</investigator_title>
  </responsible_party>
  <keyword>Donor eggs</keyword>
  <keyword>Donor oocytes</keyword>
  <keyword>Pregnancy</keyword>
  <keyword>Embryo Implantation</keyword>
  <keyword>Infertility</keyword>
  <keyword>IVF</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leuprolide</mesh_term>
    <mesh_term>Ganirelix</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

